Compare ACADIA Pharmaceuticals Inc. (ACAD) vs American Tower Corp (AMT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs American Tower Corp — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.89 (market cap $4.49B), while American Tower Corp trades at $164.7 (market cap $76.99B). The key difference: American Tower Corp is far larger — about 17.1× ACADIA Pharmaceuticals Inc.'s market cap, and American Tower Corp pays a 4.22% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | AMT | |
|---|---|---|
Market Cap | $4.49B | $76.99B |
Sector | Health | Real Estate |
52-Week High | $28.06 | $232.35 |
52-Week Low | $20.06 | $162.11 |
Enterprise Value | $3.69B | $120.51B |
Dividend Yield | — | 4.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
AMT trades at $165.25, down 0.47% on the day, with a bearish technical signal from moving averages and oscillators. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 results pending. Strong profitability is evident with a net margin of 26.81% and ROE of 82.19%, though valuation ratios like P/E of 26.15 and P/B of 21.44 appear elevated. Recent news highlights steady revenue growth and sustainability initiatives.
The outlook remains positive with a consensus price target of $217, implying significant upside, supported by 38 buy ratings and no sell recommendations. Risks include high debt levels and competitive pressures from satellite technology. The stock offers a solid dividend yield, with the next payment scheduled for July 13, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About American Tower Corp
American Tower owns and operates more than 220,000 cell towers throughout the U.S., Asia, Latin America, Europe, and Africa. It also owns and/or operates 25 data centers in eight U.S. markets after acquiring CoreSite. On its towers, the company has a very concentrated customer base, with most revenue in each market being generated by just the top few mobile carriers. The company operates more than 40,000 towers in the U.S., which accounted for more than half of its total revenue in 2021. Outside the U.S., American Tower's greatest presence is in India and Brazil, where it operates roughly 75,000 and 19,000 towers, respectively. American Tower operates as a real estate investment trust.
Read more on AMT →
